FWIW I agree I overstated my position a little when talking about other bio markers changes effected by statins. I think it is best said that the other biomarker effects of statins (lower CRP, higher HDL, specific LDL types) are gaining more and more credence as other potential, equally plausible, MOA. I.e. There is now a cloud of fog around the concept that LDL is the primary beneficial MOA of statins. And the cardiology community has been badly stung repeatedly by other highly touted bio markers that failed (repeatedly) in trials and is now backing off on all of them. Including LDL. E.g. The change in treatment guidelines in 2012/2013 (which removed HDL targets AND LDL targets largely for these reasons)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.